Description: Engineering For New Heights in the Treatment of Inflammatory Bowel Disease
ulcerative colitis (143) ibd (138) monoclonal antibodies (58) inflammatory bowel disease (54) mabs (32) crohn’s disease (31) α4β7 (26) tl1a (26) il-23 (26) uc/cd (26)
Spyre Therapeutics Acquired by Aeglea BioTherapeutics | Read More
TRANSFORMING THE TREATMENT OF INFLAMMATORY BOWEL DISEASE Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.
LinkedIn Twitter Engineering for new heights in the treatment of Inflammatory Bowel Disease Spyre Therapeutics is developing potential best-in-class antibodies, rational therapeutic combinations, and precision immunology approaches with the goal of creating Inflammatory Bowel Disease (IBD) therapies with uncompromising efficacy and convenience.